It is unclear whether supplemental glutamine is of benefit in haematopoietic stem cell transplantation (HSCT). We performed a systematic review and metaanalyses using Cochrane methodology. Seventeen randomized controlled trials (RCTs) were found. There was considerable heterogeneity between studies in terms of patient demographics and glutamine administration schedule. Many of the studies were small and scored poorly on methodological quality. Oral glutamine may reduce mucositis (average mucositis score: standard mean difference À0.38, 95% confidence interval (CI) À0.59 to À0.16) and days of opioids (mean difference À1.95 days, 95% CI À3.66 to À0.25) and GVHD (relative risk 0.42, 95% CI 0.21-0.85). Glutamine (i.v.) may reduce clinical infections (relative risk 0.75, 95% CI 0.58 to 0.97) and positive cultures (relative risk 0.72, 95% CI 0.57-0.91) but may also increase the risk of relapse (relative risk 2.91, 95% CI 1.34-6.29) but this is based on only two small studies. There was no effect of oral or i.v. glutamine on overall transplant-related mortality at day þ 100. In conclusion, there may be beneficial effects of glutamine in HSCT but larger, well-designed studies are required to confirm the beneficial effects and investigate possible adverse effects.
Introduction
Glutamine is normally a non-essential amino acid but in times of severe physiological stress it is thought that deficiency may occur. 1 Glutamine is involved in nitrogen transport, ammoniagenesis and is a preferred fuel for enterocytes, hepatocytes, lymphocytes and macrophages. 2 The gut seems particularly sensitive to glutamine deficiency, which may cause increased permeability and production of inflammatory cytokines. 3 Systematic reviews of glutamine supplementation during critical illness suggests a trend towards reduced morbidity and mortality. 4, 5 Also animal studies demonstrate that glutamine supplementation, following chemotherapy, reduces the severity of mucositis and bacterial translocation from the gut, but variable results are seen in human studies. 6 Reviews 7, 8 and guidelines 9, 10 in the area have given conflicting advice. The literature search for the Cochrane review 7 of nutritional support in haematopoietic stem cell transplantation (HSCT) patients ended in June 2006 and needs updating with new accumulating evidence. We therefore decided to perform an up-to-date systematic review with the aim of clarifying the function of glutamine supplementation in HSCT.
Materials and methods
Cochrane methodology was used for the review. 12 and the Current Controlled Studies website. 13 No language restrictions were applied. One investigator (MC) performed the search with another (AA) screening a random 500 abstracts from the database search to check agreement.
Inclusion criteria
Studies that reported predefined clinical outcomes with a glutamine (intervention) arm and a no-glutamine (control) arm were included. There were no age restrictions. Predefined clinical outcomes were mortality, relapse, infections, time to neutrophil recovery, hospital stay, mucositis, GVHD, veno-occlusive disease, transfusion requirements, weight, anthropometric changes, nausea and vomiting, total parenteral nutrition (TPN) requirements and quality of life. When it became clear there were sufficient randomized controlled trials (RCTs) for metaanalysis non-randomized studies were excluded. Studies published only in abstract form were included.
Quality assessment and data extraction For English language papers two investigators (AA and MC) performed double blinded data extraction and methodological quality assessment, whereas for foreign language papers this was performed by one reviewer. Disagreements were resolved by discussion. The full methodological quality assessment scheme can be seen in Supplementary information. Authors were contacted to resolve discrepancies and to provide information to allow meta-analysis to be performed. Authors of studies only published in abstract form were contacted and asked to provide more information on the study to allow more detailed quality assessment.
Data-analysis
Meta-analysis was conducted using RevMan 5.0.
14 Categorical data were compared using the Mantel-Haenszel method with fixed effect measures that produced relative risk (RR) with 95% confidence intervals (95% CIs). Continuous data were compared using inverse variance with fixed effect measures with data presented as mean difference (MD) with 95% CIs. Where continuous data were measured using different scales for the same outcome standard mean difference (SMD) was used. I 2 -tests 15 were performed to quantify the degree of heterogeneity. An I 2 of 50% was taken as significant and investigated. Investigation initially checked if there had been correct data entry, then subgroup analysis was undertaken. If heterogeneity persisted and I 2 was greater than 50% then random effect measures were used.
For pre-specified subgroup analysis the studies were split into the following groups (there was a post hoc decision to also present the data in subgroups, regardless of the heterogeneity):
Transplant type Studies up to and including 2000 and post-2000 studies Studies where glutamine was started before D þ 0 and studies where glutamine was started after D þ 0 Ranking studies on the dose of glutamine given to determine if there was a corresponding trend in results Comparing i.v. glutamine given alone with i.v. glutamine given within TPN.
Sensitivity analysis was performed looking at differences when:
Studies were entered which had been excluded due to methodology Reasonable values were entered into missing data Non-randomized studies were added Non-blinded studies were removed Abstracts were removed Studies were removed without intention to treat and adequate allocation concealment Commercially sponsored studies were removed Reasonable values for missing data were used where the central point of the data was given (mean or median) but no spread. The mean of the other studies' s.d. was used as a reasonable value for missing data.
A funnel plot was performed to determine if publication bias was present.
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Results
Description of the studies
The search produced 22 studies, 18 fully published and 4 published in abstract form only (Table 1) . The studies were either RCTs (17), non-randomized studies with a historical control (2) or non-randomized studies with a contemporary control (3). The search flow chart can be seen in Figure 1 . Four ongoing studies were found from the study databases. When the investigators were contacted for further information one study had reported its findings, one study had no usable data, one study was still recruiting and there was no reply from one investigator.
Glutamine was administered either orally [16] [17] [18] [22] [23] [24] 29, 31, 39 or i.v. [19] [20] [21] [25] [26] [27] [28] 30, [32] [33] [34] [35] [36] [37] [38] [40] [41] [42] [43] [44] [45] [46] [47] [48] (either by continual infusion with TPN or as a bolus). There was considerable heterogeneity between the studies in terms of patient characteristics, transplant type, glutamine dose, start and finish times of the intervention and underlying disease. Age varied with one study including only paediatric patients, 18 one study including both adults and children, 16, 17 and the remaining studies included just adults [19] [20] [21] [24] [25] [26] [27] [28] 30, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [45] [46] [47] or gave no information on age. 22, 23, 29, 31 Trials included all allogeneic transplants, 19, 25, 26, 31, [44] [45] [46] [47] all autologous 22, 23, 29, [32] [33] [34] [35] [36] [37] [40] [41] [42] [43] 48 or a mixture of both. [16] [17] [18] 20, 21, 24, 27, 28, 38, 39 The studies were from 1992 until the present leading to changes in underlying diseases with time. The dosing schedule was variable with studies starting glutamine before D þ 0 [16] [17] [18] [19] [20] [21] 24, 31, [40] [41] [42] [43] whereas others started after D þ 0 [25] [26] [27] [28] [29] [34] [35] [36] [44] [45] [46] [47] and had variable stopping times. Doses were either on a per kg basis or a fixed dose. The differences in dosing schedules led to a wide range of doses from 1.02 g/kg 18 to 7.31 g/kg 24 by day þ 10 (assuming a 70 kg patient). Table 1 lists the dosing schedule of the studies. Full details of the studies can be seen in Supplementary information.
Methodological quality of the studies
On the whole, the quality of reporting of the studies was poor with only four 18, 25, 26, [34] [35] [36] [37] [38] 48 out of 17 studies reporting optimal allocation concealment ( Table 2 ). More studies, No studies reported blinded patients, assessors, care providers and data analysers altogether but five studies 16, 17, 19, 25, 26, [34] [35] [36] [37] [40] [41] [42] [43] 48 reported blinding all but the data analysers.
An abridged version of the quality assessment can be seen in Table 2 with full quality assessment in the Supplementary information.
Meta-analysis
Meta-analysis could be performed for 11 out of the 15 outcomes of interest. Only the main forest plots are displayed in this article. Additional forest plots, including for subgroup and sensitivity analyses, where calculable, can be found in the Supplementary information. A summary table of all the meta-analyses is provided (Table 3) .
Mortality
Mortality was reported as deaths up to and including D þ 100 and deaths after D þ 100.
Three studies (379 patients) reported mortality up to D þ 100 with oral glutamine and found no statistically significant effect (RR 0.94, 95% CI 0.58-1.51, I
2 ¼ 36%). Five studies reported mortality up to D þ 100 (193 patients) with i.v. glutamine and similarly demonstrated no effect (RR 0.78, 95% CI 0.43-1.43, I
2 ¼ 0%). When oral and i.v. studies were combined, glutamine had no effect on mortality up to D þ 100 (RR 0.88, 95% CI 0.60-1.27, I
2 ¼ 0%) (Figure 2 ). Subgroup and sensitivity analyses did not change these results. One study reported mortality after D þ 100 with oral glutamine. Three studies (137 patients) reported mortality after D þ 100 with i.v. glutamine; there appears to be no statistically significant effect of glutamine (RR 1.12, 95% CI 0.65-1.92) but with considerable heterogeneity (I 2 ¼ 78%) ( Figure 2 ). Two studies of autologous transplants only 19, [34] [35] [36] [37] [40] [41] [42] [43] suggested an increased mortality with glutamine (combined effect RR 3.21, 95% CI 1.17-8.79, I
2 ¼ 0%) whereas the single study 25, 26 that suggested decreased mortality investigated allogeneic transplants only and the excess deaths in the control arm all occurred in the first 100 days. Figure 1 Flow chart of study selection. RCT, randomized controlled trial; NHC, non-randomized historical control; NCC, non-randomized contemporary control. Bold type signifies a significant result. 2 ¼ 0%) (Figure 3 ). Sensitivity analysis revealed that removing studies that either did not have adequate allocation concealment, did not perform intention-to-treat analysis or were commercially sponsored meant that the results were no longer statistically significant although in each case only three studies were left.
Infections
The number of positive cultures was reported by two studies using oral glutamine (172 patients) and demonstrated no statistically significant effect of glutamine (RR 1.09, 95% CI 0.69-1.57, I
2 ¼ 0%). Four studies reported a number of positive cultures with i.v. glutamine and demonstrated a reduction (RR 0.72l, 95% CI 0.57-0.91, I
2 ¼ 0%). Overall, the effect of i.v. and oral glutamine combined was a trend towards fewer positive cultures (RR 0.83, 95% CI 0.67-1.02, I 2 ¼ 28%) (Figure 3 ) that was not altered by sensitivity analysis.
Three studies of i.v. glutamine reported days of fever in 116 patients. One study only reported 'no statistical Figure 2 Forest plots of mortality. Figure 3 Forest plots of infections.
Glutamine and HSCT M Crowther et al severe mucositis, maximum mucositis score and days of opioids (as a surrogate marker). As different mucositis scores were used throughout, SMDs were used. Three studies compared oral glutamine with placebo (329 patients) and reported average mucositis score. The overall effect was a reduction in the average mucositis score (SMD À0.38, 95% CI À0.59 to À0.16, I
2 ¼ 27%). Glutamine (i.v.) was studied in four studies (145 patients) and demonstrated no statistically significant effect of glutamine (SMD 0.08, 95% CI À0.25, 0.41, I
2 ¼ 40%). The overall effect of oral and i.v. glutamine was a reduced average mucositis score (SMD À0.24, 95% CI À0.42 to À0.05, I
2 ¼ 48%) (Figure 4) . Subgroup analyses revealed a trend towards a lower average score if the glutamine was started before D þ 0 compared to after (P ¼ 0.09). Other subgroup and sensitivity analyses did not change the results.
Four studies (131 patients) reported days of mucositis as an outcome with oral glutamine (SMD À0.26 days, 95% CI À1.02-0.50, I
2 ¼ 59%). One study's data could not be used because no spread of data was given, although medians were the same. The heterogeneity came from one study 22, 23 but there is no obvious reason why this study is different. Adding the only i.v. glutamine study gave an overall effect of an SMD of À0.31 days (95% CI À0.82 to 0.20, I
2 ¼ 45%) (Figure 4 ). Subgroup and sensitivity did not change this result. Two studies with 52 patients on oral glutamine reported the presence of severe mucositis. Meta-analysis found an RR of 0.81 (95% CI 0.58-1.14, I
2 ¼ 46%). Only one study reported maximum mucositis score for oral glutamine. Two studies reported maximum mucositis score for i.v. glutamine (87 patients) SMD À0.09 (95% CI À1.15 to 0.96, I
2 ¼ 83%). When these three studies are combined the overall result was SMD À0.09 (95% CI À0.61 to 0.43, I
2 ¼ 67%). There were insufficient studies to investigate the heterogeneity further. Four studies of oral glutamine (352 patients) reported days of opioids. The combined effect was fewer days of opioids with oral glutamine (MD À1.95 days, 95% CI À3.66 to À0.25, I
2 ¼ 82%). Only one study reported the outcome with i.v. glutamine. When the i.v. and oral studies were combined, overall there was no statistically significant effect on days of opioids with glutamine (MD À0.21 days, 95% CI À1.52 to 1.10, I
2 ¼ 84%). The heterogeneity appeared to come from the allogeneic transplants in one study. 16, 17 Subgroup analysis found that a greater reduction in days of opioids was seen if the glutamine was given before D þ 0 (P ¼ 0.03). Both removal of non-blinded assessors and commercially sponsored studies reduced the effect.
GVHD
Two studies investigating oral glutamine (75 patients) reported GVHD and found a reduction in GVHD with glutamine (RR 0.42, 95% CI 0.21-0.85, I
2 ¼ 13%). GVHD was reported in four studies of i.v. glutamine (164 patients) and these found no statistically significant effect of glutamine (RR 0.85, 95% CI 0.60-1.22, I
2 ¼ 39%). The overall effect of i.v. and oral glutamine on GVHD was a reduction in GVHD (RR 0.73, 95% CI 0.53-0.99, I
2 ¼ 47%). Subgroup analysis suggested a benefit for starting glutamine before D þ 0 with a greater overall reduction in GVHD (P ¼ 0.012). Removal of studies without adequate assessor blinding and intention to treat leaves only studies demonstrating no benefit for glutamine.
Time to neutrophil recovery
Five studies (160 patients) investigated oral glutamine and time to neutrophil recovery, two studies reported data in an unusable format, 'no statistical difference' and no spread of data was given. Oral glutamine demonstrated no statistically significant effect (MD À0.39 days, 95% CI À1.79 to 1.01, I 2 ¼ 0%). Time to neutrophil recovery was reported in seven studies with i.v. glutamine (276 patients), one study reported spread of data as range and hence could not be used. When the studies were combined the result was MD À0.76 days (95% CI À1.85 to 0.34, I
2 ¼ 28%). Overall the result of oral and i.v. glutamine was MD À0.62 days (95% CI À1.48 to 0.25, I
2 ¼ 0%). Subgroup and sensitivity analysis demonstrated a reduced effect of glutamine when non-assessor blinded studies were removed but an increased effect when studies without intention to treat were removed.
Length of hospital stay
Four studies reported length of stay with oral glutamine (246 patients). One study's results could not be used as it reported range for spread of data. The overall effect of oral glutamine was a trend towards a reduced length of stay (MD À2.59 days, 95% CI À5.21 to 0.02, I
2 ¼ 0%). Length of stay was an outcome in eight studies with i.v. glutamine and the overall effect was not statistically significant, MD 0.41 days (95% CI À0.89 to 1.71, I
2 ¼ 42%). Two studies data could not be used as one presented the spread as a range and the other reported 'no statistical difference'. Overall, when oral and i.v. glutamine were combined, there was no effect of glutamine on length of stay (MD 0.41 days, 95% CI À0.89 to 1.71, I
2 ¼ 36%). Subgroup analysis suggested that the effect of increased length of stay is mainly from one study [34] [35] [36] [37] 48 and is therefore limited to autologous transplants and to studies published after 2000. The addition of missing data reduces the effect of glutamine.
Time to platelet recovery One study using oral glutamine reported time to platelet recovery. Four studies with i.v. glutamine (148 patients) reported time to platelet recovery, although only two had usable data, they demonstrated no statistically significant effect of glutamine (MD 0. 33 2 ¼ 71%). There were too few studies to investigate the heterogeneity further.
Days of TPN
Five studies reported days of TPN with oral glutamine (246 patients) (but data from two studies could not be used due to reporting of spread of data as range and reporting 'no statistical difference'), the combined effect was no statistically significant difference in the days of TPN with oral glutamine (MD À0.69 days, 95% CI À3.79 to 2.41, I
2 ¼ 70%). On investigation, the heterogeneity seemed to be coming from one study. 29 There was no obvious reason for this, the MD with this study excluded was À5.44 days (95% CI À9.69 to À1.19, I
2 ¼ 0%). Five studies reported days of TPN with i.v. glutamine (195 patients) and the combined effect was MD À0.89 days (95% CI À2.61 to 0.82, I
2 ¼ 20%). One i.v. glutamine study could not be used because it presented spread of data as range, median days 18 vs 17.9 for glutamine and control. The overall effect of i.v. and oral glutamine on days of TPN was MD À0.84 days (95% CI À2.35 to 0.66, I 2 ¼ 53%). Sensitivity analysis suggested removal of non-blinded studies, studies with poor allocation concealment, lack of intention to treat and commercial sponsorship reduced the effect of glutamine, although the number of studies left was small.
Blood transfusions
Three studies (114 patients) reported the number of red cell transfusions with i.v. glutamine and the combined effect was a trend towards more transfusions in the glutamine arm (MD 1.05 transfusions, 95% CI À0.35 to 2.44,
Four studies (142 patients) reported number of platelet transfusions, although one study's data could not be used as the investigators stated that there was 'no statistically significant difference'. Overall there was no effect of glutamine on platelet transfusions (MD 0.22 transfusions, 95% CI À1.00 to 1.44, I
2 ¼ 0%).
Funnel plots
There were insufficient studies in each outcome to produce meaningful funnel plots to test publication bias.
Discussion
It appears that our search strategy was successful as none of the studies found in the previous reviews was missed. We think that the decision to exclude non-randomized studies was correct, as with previous reports 49 they tended to increase the effect size and were more open to confounding factors.
Oral and i.v. glutamine appear to have differing effects. There is no apparent reason why this should be the case. Dose finding experiments, for oral glutamine, in patients with and without mucositis, have demonstrated that oral glutamine at lower doses than used in all but two [16] [17] [18] of the studies causes an increase in blood glutamine levels, suggesting adequate absorption and the possibility for systemic actions. 50, 51 Glutamine (i.v.), when administered with TPN, produces improvement in gut function and less gut atrophy, suggesting i.v. glutamine has effects locally on the gut mucosa. 52 Oral glutamine appears to have no effect on mortality, infections, time to neutrophil recovery or relapses. Oral glutamine does appear to reduce mucositis (decreased average score and fewer days of opioids and trends for less days of mucositis and less severe mucositis) and GVHD (which may be due to mucositis being a risk factor for GVHD 53, 54 ). There are also trends towards reduced length of stay and length of time on TPN. The suggestion that a greater reduction in mucositis and GVHD is seen when the glutamine is administered before D þ 0 suggests glutamine's primary function is reducing damage to the gut by the chemoradiotherapy conditioning, probably acting as an antioxidant through the glutathione pathway.
Glutamine (i.v.) appears to have no effect on D þ 100 mortality, mucositis, GVHD and platelet recovery. Glutamine (i.v.) does appear to reduce infections measured by either number of positive cultures or clinical infections, the reduction being similar to that as seen in critical illness. 4 Glutamine does not seem to effect surrogate measures of infections (antibiotics and fever) but this may be due to fever also being caused by other factors such as cytokine release and mucositis. Antibiotic therapy, in neutropenic patients, is usually guided by fever rather than presence or absence of positive cultures. It also appears to increase long-term mortality, possibly through a higher relapse rate, but this is based on two small studies in autologous transplants. There have been several reasons suggested for the higher relapse rate including 'feeding the tumour', 6 a greater antioxidant potential hence less free radical damage to the tumour during chemo-and radiotherapy and the upregulation of T-helper cells, 55 which may contribute to the tumour evading the immune system. 56 Future studies may look at the effects on T regulatory cells.
Glutamine is inexpensive (d29.60 per day for i.v. glutamine, based on 200 mg/kg per day for a 70 kg patient) 57 and d2.89 per day for oral glutamine (for 5 g four times per day, S Howlett, personal communication) therefore small reductions in mucositis, GVHD and infections would appear economically viable. This would be greater for oral glutamine that does not seem to carry the possibility of increasing long-term relapse risk.
There are several limitations to this review. There was considerable heterogeneity of the studies in terms of transplant type, dosing of glutamine and underlying disease with insufficient numbers for meaningful subgroup analysis. The most obvious area of heterogeneity is comparing different transplant types, as there are major differences in the complication rates and underlying mechanisms of conditioning and engraftment between allogeneic and autologous transplants. However, if glutamine's beneficial action is on patients with critical illness then it should act equally well in both groups of patients who are 'critically unwell' due to the transplant.
Indications for transplantation have changed considerably over the time that glutamine studies have been performed, with a reduction in solid tumour transplants. Glutamine may also have different effects depending on the underlying disease. Supportive care has improved over time, and therefore any beneficial effect may be lessened in later studies. Further heterogeneity may come from different age groups who are affected differently by transplants. There is no way of knowing if glutamine given to an adult with myelodysplastic syndrome will have the same effect as if it were given to a child with ALL. There is also no firm consensus on the optimal dosing regimen.
The general methodological reporting of the studies was poor, and, as the sensitivity analysis proved, removing studies that had failed to report assessor blinding, intention to treat and allocation concealment tended to cause a reduction in the beneficial effects of glutamine. This confirms earlier findings that studies with poor reporting tend to report greater differences. 58 In comparison with the Cochrane review 7 this review found and included two 22, 23, 31 extra studies of oral glutamine and five 19, [25] [26] [27] [28] 32, 33, [40] [41] [42] [43] extra using i.v. glutamine. These extra studies led to a difference in the results between the reviews. In the Cochrane review with regard to oral glutamine the only significant result was an increased time to neutrophil recovery with glutamine whereas i.v. glutamine only demonstrated a trend towards fewer positive cultures. The increased number of i.v. studies may be because the Cochrane review only included glutamine given as part of TPN. The Cochrane review authors recommend that if TPN is required during HSCT then it should be glutamine supplemented.
In summary, glutamine may have beneficial effects in HSCT. Oral glutamine may reduce mucositis and GVHD whereas i.v. glutamine may reduce infections. However, these findings are based on mainly small, poorly reported studies. Although a relatively cheap intervention, with the possibility of increased relapse, the authors feel that the routine use of glutamine cannot be recommended at present. For definitive answers larger well-designed RCTs are required, which report detail according to the CONSORT statement. 59 
